Psoriasis on Skin: Plaques, Triggers & Treatment Options

What Is Psoriasis?

Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by well-demarcated, erythematous (red) plaques covered with silvery-white scales. It is not contagious and is not caused by poor hygiene. The underlying mechanism is systemic — an overactivated immune response drives keratinocytes (the main cells of the skin's outer layer) to proliferate every 3–5 days instead of the normal 28–30 day turnover cycle, causing cells to build up faster than they shed.

Psoriasis affects approximately 2–3% of the global population — an estimated 125 million people worldwide. It can appear at any age but shows two peaks of onset: early-onset (bimodal peak in the late teens to early 30s) and late-onset (around ages 50–60). Men and women are equally affected.

The Biology: Why Psoriasis Happens

Psoriasis develops at the intersection of genetic predisposition and immune dysregulation. Over 80 genetic loci have been associated with psoriasis risk; the HLA-Cw6 allele is the single strongest genetic risk factor, particularly linked to early-onset plaque psoriasis.

The central immune axis driving psoriasis is the TNF-α / IL-23 / IL-17 pathway:

1. Environmental or internal triggers (infection, trauma, stress) activate plasmacytoid dendritic cells and myeloid dendritic cells in the dermis.
2. These dendritic cells release IL-12 and IL-23.
3. IL-23 drives naïve T cells to differentiate into Th17 and Th1 subtypes.
4. Th17 cells release IL-17A, IL-17F, and IL-22; Th1 cells release TNF-α and IFN-γ.
5. These cytokines act on keratinocytes, triggering rapid proliferation, incomplete differentiation, and secretion of further inflammatory mediators — creating a self-amplifying inflammatory loop.
6. The result at the skin surface: parakeratosis (nuclei retained in the stratum corneum), acanthosis (thickening of the living epidermis), and tortuous blood vessel proliferation in the dermis producing the characteristic red color.

This understanding of the IL-23/IL-17 axis directly underpins the most effective modern biologic treatments.

Types of Psoriasis

Plaque Psoriasis (Psoriasis Vulgaris)

The most common form, accounting for roughly 90% of all psoriasis cases. Characterized by raised, well-defined oval or irregular plaques with a silvery-white scale on a red base. Common sites are the elbows, knees, lower back, and scalp. Plaques can range from a few centimeters to extensive body surface involvement.

Guttate Psoriasis

Small (0.5–2 cm), drop-shaped pink papules scattered across the trunk and limbs. Most common in children and young adults. Frequently triggered by a streptococcal throat infection occurring 2–6 weeks prior. Around 40% of people with guttate psoriasis progress to chronic plaque psoriasis.

Pustular Psoriasis

Pus-filled blisters (pustules) surrounded by red skin. Comes in palmoplantar (limited to palms and soles) and generalized forms. Generalized pustular psoriasis (von Zumbusch type) can be life-threatening and requires urgent medical treatment.

Inverse (Flexural) Psoriasis

Occurs in skin folds — axillae, groin, under the breasts, around the genitals. The plaques are smooth, shiny, and moist rather than scaly because scale is macerated by friction and sweat. Frequently complicated by secondary candidal infection.

Erythrodermic Psoriasis

A rare but severe form in which psoriasis spreads to cover more than 90% of body surface area. A medical emergency: it disrupts temperature regulation, protein balance, and can lead to high-output cardiac failure. Requires hospital admission.

Nail Psoriasis

Nail involvement occurs in up to 50% of people with plaque psoriasis and up to 80% of those with psoriatic arthritis. Features include pitting, onycholysis (nail plate separating from the bed), oil-drop discoloration, and subungual hyperkeratosis.

Common Triggers

Identifying personal triggers is a cornerstone of long-term psoriasis management. The most consistently documented triggers are:

Psoriasis and Comorbidities

Psoriasis is a systemic inflammatory disease, not just a skin condition. Chronic IL-17 and TNF-α signaling affects multiple organ systems. Dermatologists and guidelines recommend screening for:

Psoriatic Arthritis (PsA): Occurs in 20–30% of patients with psoriasis. It typically affects joints of the fingers and toes (dactylitis), spine, and larger joints. PsA can cause permanent joint damage if untreated; early identification and referral to rheumatology is critical.

Cardiovascular disease: People with moderate-to-severe psoriasis have a significantly elevated risk of myocardial infarction, stroke, and cardiovascular mortality — independent of traditional risk factors. The shared inflammatory pathways (TNF-α, IL-6, atherosclerosis) explain this link. Metabolic syndrome (hypertension, dyslipidemia, type 2 diabetes, obesity) is more prevalent in psoriasis patients.

Inflammatory bowel disease: Crohn's disease and psoriasis share IL-23/Th17 pathway involvement; the two conditions coexist more often than chance would predict.

Depression and anxiety: The visible, chronic nature of psoriasis substantially affects mental health and quality of life. The AAD recognizes depression screening as part of comprehensive psoriasis care.

Uveitis: Inflammatory eye disease, particularly uveitis, is more common in psoriasis, especially in those with psoriatic arthritis.

Diagnosis

Psoriasis is primarily a clinical diagnosis made by a dermatologist based on examination findings. No blood test diagnoses psoriasis. Skin biopsy may be used when the diagnosis is uncertain; histology shows characteristic acanthosis, parakeratosis, dilated dermal capillaries, and neutrophilic infiltration.

Disease severity is assessed using validated scoring tools:

• PASI (Psoriasis Area and Severity Index): The standard measure in clinical trials; scores the extent and severity of redness, thickness, and scaling across four body regions.
• BSA (Body Surface Area): The percentage of skin surface affected.
• DLQI (Dermatology Life Quality Index): Captures patient-reported quality-of-life impact.

Treatment Options

Treatment is matched to disease severity, affected body sites, comorbidities, patient preference, and response history. There is no cure — the goal is sustained clearance with the safest effective regimen.

Topical Therapies (Mild–Moderate Disease)

Topical corticosteroids are the most widely prescribed first-line agents. They suppress local inflammation and reduce keratinocyte proliferation. Potency is matched to body site: high-potency agents (clobetasol propionate) for body plaques; mid-potency for sensitive areas; low-potency for face and flexures. Long-term continuous use risks skin atrophy, so dermatologists typically rotate with steroid-sparing agents.

Vitamin D analogues (calcipotriol/calcitriol): Slow keratinocyte proliferation and normalize differentiation by binding to vitamin D receptors. Often used in combination with a corticosteroid — the combination is more effective than either agent alone and reduces long-term steroid exposure.

Topical retinoids (tazarotene): A synthetic retinoid that normalizes cell differentiation and reduces inflammation. Combined with a corticosteroid for improved tolerability.

Calcineurin inhibitors (tacrolimus, pimecrolimus): Non-steroidal anti-inflammatory agents particularly useful for facial and flexural psoriasis where prolonged corticosteroid use is not appropriate.

Salicylic acid: Used as a keratolytic agent to soften and lift scale, enhancing penetration of other topicals. Typically 2–10% in a suitable base.

Tapinarof and roflumilast (newer topicals): FDA-approved aryl hydrocarbon receptor agonist and PDE4 inhibitor respectively — non-steroidal options with clinical trial data supporting efficacy in plaque psoriasis.

Phototherapy (Moderate Disease)

Narrowband UVB (NB-UVB) is the phototherapy standard. Administered 3 times weekly (or less frequently with a careful protocol), it suppresses activated T cells in the skin and produces remission in many patients. It is safe in pregnancy and for children.

PUVA (psoralen + UVA): Psoralen sensitizes the skin before UVA exposure. More effective than NB-UVB for palmoplantar disease but carries a cumulative long-term skin cancer risk, limiting total lifetime dose.

Systemic Non-Biologic Agents (Moderate–Severe Disease)

• Methotrexate: An antifolate that suppresses rapidly dividing cells and has anti-inflammatory effects. Effective for both skin and joints. Requires monitoring for hepatotoxicity and myelosuppression.
• Cyclosporine: A calcineurin inhibitor taken orally. Fast-acting, useful for severe flares. Limited to short-term use due to nephrotoxicity and hypertension risk.
• Acitretin: An oral retinoid, particularly useful for pustular and erythrodermic psoriasis. Teratogenic with a very long washout period; restricted use in women of childbearing potential.
• Apremilast: An oral PDE4 inhibitor that reduces inflammatory cytokine production. Moderate efficacy; well tolerated without the monitoring burden of immunosuppressants.

Biologic Therapies (Moderate–Severe Disease)

Biologics are the most powerful agents available for psoriasis and represent the therapeutic revolution of the past two decades. They are large-molecule proteins administered by injection or infusion that target specific cytokines or receptors in the IL-23/IL-17/TNF-α axis:

IL-23 p19 inhibitors and IL-17 inhibitors currently show the highest PASI 90/100 response rates in head-to-head trial data. Biologics require screening for latent tuberculosis and hepatitis B before initiation and periodic monitoring during treatment.

When to See a Dermatologist

Self-management and emollient use may help mild psoriasis, but a dermatologist should be consulted if:

• Psoriasis is moderate to extensive (affecting more than a few patches)
• Plaques affect the face, genitals, palms, soles, or nails
• Joints are painful or swollen (possible psoriatic arthritis — urgent referral)
• OTC or general practitioner treatments are not controlling the condition
• Psoriasis is affecting mental health, work, or daily activities
• A flare of unusual severity (especially erythrodermic or generalized pustular pattern) occurs — this requires urgent or emergency care